Article
Integrative clinical genomics of advanced prostate cancer.
Cell - 21 May 2015
Robinson Dan, Van Allen Eliezer M, Wu Yi-Mi, Schultz Nikolaus, Lonigro Robert J, Mosquera Juan-Miguel, Montgomery Bruce, Taplin Mary-Ellen, Pritchard Colin C, Attard Gerhardt, Beltran Himisha, Abida Wassim, Bradley Robert K, Vinson Jake, Cao Xuhong, Vats Pankaj, Kunju Lakshmi P, Hussain Maha, Feng Felix Y, Tomlins Scott A, Cooney Kathleen A, Smith David C, Brennan Christine, Siddiqui Javed, Mehra Rohit, Chen Yu, Rathkopf Dana E, Morris Michael J, Solomon Stephen B, Durack Jeremy C, Reuter Victor E, Gopalan Anuradha, Gao Jianjiong, Loda Massimo, Lis Rosina T, Bowden Michaela, Balk Stephen P, Gaviola Glenn, Sougnez Carrie, Gupta Manaswi, Yu Evan Y, Mostaghel Elahe A, Cheng Heather H, Mulcahy Hyojeong, True Lawrence D, Plymate Stephen R, Dvinge Heidi, Ferraldeschi Roberta, Flohr Penny, Miranda Susana, Zafeiriou Zafeiris, Tunariu Nina, Mateo Joaquin, Perez-Lopez Raquel, Demichelis Francesca, Robinson Brian D, Schiffman Marc, Nanus David M, Tagawa Scott T, Sigaras Alexandros, Eng Kenneth W, Elemento Olivier, Sboner Andrea, Heath Elisabeth I, Scher Howard I, Pienta Kenneth J, Kantoff Philip, de Bono Johann S, Rubin Mark A, Nelson Peter S, Garraway Levi A, Sawyers Charles L, Chinnaiyan Arul M
Abstract excerpt
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases),...
Read the complete abstract on PubMed